Capital Group Private Client Services, Inc. Ultragenyx Pharmaceutical Inc. Transaction History

Capital Group Private Client Services, Inc.

$9.94 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$62.2 - $84.4 $3.61 Million - $4.89 Million	-57,963 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$73.71 - $87.86 $163,709 - $195,137	-2,221 Reduced 3.69%	57,963 $4.87 Million
Q3 2021 Nov 15, 2021	BUY	$77.92 - $102.4 $4.69 Million - $6.16 Million	60,184 New	60,184 $5.43 Million

Others Institutions Holding RARE

# of Institutions

325

Shares Held

85.6M

Call Options Held

520K

Put Options Held

406K

Vanguard Group Inc Valley Forge, PA

9.95M
Shares

$446 Million
0.01% of portfolio
Black Rock Inc. New York, NY

5.6M
Shares

$251 Million
0.01% of portfolio
Sands Capital Management, LLC Arlington, VA

5.12M
Shares

$230 Million
0.91% of portfolio
Wellington Management Group LLP Boston, MA

4.17M
Shares

$187 Million
0.04% of portfolio
Price T Rowe Associates Inc Baltimore, MD

3.07M
Shares

$138 Million
0.02% of portfolio

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.14B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Group Private Client Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Capital Group Private Client Services, Inc. with notifications on news.

Account